In the current trading session, the stock has seen a change of -11.64% recently hitting $4.48. They issued a neutral rating and a $31.00 price objective for the company. At recent closing price of $23.75, TEVA has a chance to add $13.16 or 55.41% in 52 weeks, based on mean target price ($36.91) placed by analysts.The analyst consensus opinion of 2.5 looks like a hold. 21 analysts on average projected earnings of $1.25 per share for the current quarter.
Teva Pharmaceutical Industries Limited's average Book Value per Share Growth Rate was 2 percent during the past 12 months. Guggenheim Capital LLC increased its position in Teva Pharmaceutical Industries by 1.1% in the fourth quarter. Maxim Group maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, February 13 with "Hold" rating. Nineteen equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of "Hold" and an average target price of $42.23. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since August 3, 2016 and is downtrending. The share price has moved backward from its 20 days moving average, trading at a distance of -25.98% and stays -23.81% away from its 50 days moving average. The company has a market capitalization of $21.09 billion, a P/E ratio of 266.1423 and a beta of 0.46.
Teva Pharmaceutical Industries Limited is a pharmaceutical company. Cribstone Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. The company reported $1.02 EPS for the quarter, missing the consensus estimate of $1.06 by $0.04. The return on equity ratio or ROE stands at 4 percent while most common profitability ratio return on investment (ROI) was 3.6 percent.
Teva is "on track" to pay back $5 billion of debt and meet its covenants this year, which require the company's net debt to be no greater than 4.25 times its earnings before interest, taxes, depreciation and amortization, interim Chief Financial Officer Michael McClellan said on the call. During the same quarter in the prior year, the company earned $1.25 EPS. It cut its full-year revenue expectations to $22.8 billion-$23.2 billion, from $23.8 billion-$24.5 billion. Currently Teva Pharmaceutical Industries Limited (TEVA) stock is moving with downswing trend. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading on Thursday. If you are accessing this news story on another site, it was illegally copied and reposted in violation of global trademark & copyright legislation. By looking into the stock's recent history, we can find some indicators as to why the numbers dropped today.
Teva said the second quarter 2017 dividend would be 8.5 cents, down 75% from 34 cents in the first quarter of 2017. Ledyard National Bank now owns 4,500 shares of the company's stock valued at $149,000 after buying an additional 1,475 shares during the last quarter. Sei Investments Co. now owns 1,721,466 shares of the company's stock valued at $57,188,000 after buying an additional 875,789 shares in the last quarter. Lincluden Management Ltd. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. On Monday, July 27 the stock rating was maintained by Maxim Group with "Buy".
Several institutional investors have recently modified their holdings of the company.
Acting Teva CEO Dr. Yitzhak Peterburg addressed the reports, explaining that the company had not expected such poor results and pointed to the crisis in Venezuela as part of the problem. "We have made important progress and it has been positive so far", he said, also deflecting questions from analysts on the prospects of splitting the company into two - generics and specialty drugs.